Regeneron Pharmaceuticals, Inc. (REGN)
Pre-market:
| Previous close | 820.90 |
| Open | 825.55 |
| Bid | 750.05 x 1000 |
| Ask | 855.95 x 1000 |
| Day's range | 824.82 - 841.87 |
| 52-week range | 668.00 - 853.97 |
| Volume | |
| Avg. volume | 452,990 |
| Market cap | 91.052B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 23.86 |
| EPS (TTM) | 35.03 |
| Earnings date | 01 Feb 2024 - 05 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 920.09 |
Simply Wall St.Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?
Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 1.4% over the past week. Since the market usually pay for a...
GlobeNewswireUpdated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up Data to be submitted to regulatory authorities, with Biologics License Application on track to be submitted to the FDA this year Regeneron to host virtual investor event to discuss results alongside updates across its hematology portfolio on Thursday, December 14 at 8:30 a.m. ET TARRYTOWN, N.Y., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today an
- GlobeNewswire
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
First dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo® (cemiplimab) showed encouraging initial activity in patients with recurrent ovarian cancer Additional data include a late-breaking oral presentation of first results for neoadjuvant Libtayo in combination with low-dose stereotactic body radiotherapy in early-stage hepatocellular carcinoma TARRYTOWN, N.Y., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN
